Genome Editing Biotech EdiGene Raises $10 Million in Series pre-B Plus Financing and Strengthens Management Team
BEIJING, CHINA and CAMBRIDGE, MASSACHUSETTS, US – (February 4th , 2019) – EdiGene Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery, today announced the successful completion of approximately $10 Million in a Series pre-B Plus financing, and strengthening of its management team by naming Yun Li, MD, as Vice President of Clinical Development.
The new round of financing is led by new investor Green Pine Capital Partners (Green Pine). Series A lead investor IDG Capital, Series Pre-B lead investor Lilly Asia Ventures (LAV) and other insiders also participated in this round.
“We are excited to participate in this round,” said Fei Luo, founding partner of Green Pine. “We are happy to support EdiGene’s top scientists and experienced management team to accelerate the development of breakthrough therapies to treat unmet medical needs”
“We are pleased to complete this new round of financing led by Green Pine with participation of existing investors,” said Dr. Wensheng Wei, founder of EdiGene. “As we are advancing our sciences, we look forward to working with Green Pine and our current investors to grow EdiGene into the next exciting phase.”
Separately, Yun Li, MD, has joined EdiGene as Vice President of Clinical Development. Dr. Li has more than 20 years experiences in clinical trials of novel therapeutics, mainly focusing on oncology & hematology and immunological phase I-III clinical trials. Before EdiGene, Dr. Li had been with Parexel for over 10 years as Medical director in Global Medical Service. Prior to that, she had taken various roles with increasing responsibilities in clinical development in Novartis China, Roche China, RHONE-POUULENC RORER (now Sanofi) and Xian Janssen ( J&J company). Before that, she had 10 years practice in clinical and teaching institutions. Dr. Li has a medical degree of M.Sc in Clinical Hematology and B.Sc. in General Medicine from Second Military Medical University (Shanghai, China).
“Our portfolio is entering into an exciting stage, and this new round of financing further validates and continues to support our strategy of translating proprietary platforms into potential therapeutics to patients in need,” said Dong Wei, Ph.D.,MBA，CEO of EdiGene, “We are thrilled that Dr. Li joins us at this significant point of our company’s development. Her extensive experiences in clinical development in hematology and oncology will help us advance our therapeutic candidates into clinics in the near future.”
EdiGene Inc is founded in 2015, and now headquartered in Beijing, with operational subsidiaries in Guangzhou, China and Cambridge, USA. Our mission is to translate the cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer, and into creative solutions to advance drug discovery. We leverage our proprietary platforms to develop gene-editing therapies for a wide range of diseases, and to conduct high-throughput genome screening to enable dissection of functional big data in biological contexts.